Fidelity Investments
IOBT

Fidelity Investments’s IO Biotech IOBT Stock Holding History

Fidelity Investments’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-314,600
Closed -$368K – 5615
2024
Q2 		$368K Hold
314,600
– – ﹤0.01% 2836
2024
Q1 		$551K Buy
+314,600
New +$546K ﹤0.01% 2689

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fidelity Investments's IOBT Position: Q3 2024 in Review

Fidelity Investments sold out of IO Biotech (IOBT) in Q3 2024, closing a stake of 314,600 shares — an estimated $368K sold.

Fidelity Investments first reported a position in IOBT in Q1 2024 and held it in 2 quarters. The position peaked at $551K in Q1 2024. 20 funds tracked by Wall St. Rank hold IOBT as of Q3 2024.

  • Fidelity Investments reported no remaining IO Biotech position as of Q3 2024 after selling out during the quarter.
  • Fidelity Investments sold 314,600 IO Biotech shares in Q3 2024, an estimated $368K.
  • Fidelity Investments first reported a position in IO Biotech in Q1 2024 and held it in 2 quarters.
  • Fidelity Investments's IO Biotech position peaked at $551K in Q1 2024.
  • 20 funds tracked by Wall St. Rank held IO Biotech as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.